Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2003

View Archived Issues

Sodium oxybate improves pain, fatigue and sleep patterns in fibromyalgia patients

PDE inhibitor counteracts sexual dysfunction associated with fluoxetine use

Use of oxymetholone to counter HIV wasting

VIP as a potential treatment for patients with primary pulmonary hypertension

First human data and further preclinical findings discussed for CAB-175

Solifenacin succinate safe and effective in patients with overactive bladder

Four series of inhibitors of IGF-1R, IR and IRR identified at Merck

Novel alpha7 nAChR agonists and their use described by P&U (Pfizer)

Pfizer presents new PDE9 inhibitors with utility in hypertension therapy

Novel series of NR2B-selective NMDA antagonists covered by Roche patent

Roche claims new retinoid agonists with utility in emphysema, cancer and dermatological disorders

Tau protein kinase inhibitors designed by Mitsubishi and Sanofi-Synthelabo scientists

Novel series of HIV integrase inhibitors presented by Italian researchers

Higher GI-related expenses for Fosamax patients versus Actonel patients

INS-37217 Intranasal fails to meet primary endpoint in perennial allergic rhinitis trial

Phase I trial of interferon enhancer EMZ-701 completed

CPMP contraindicates concomitant use of repaglinide and gemfibrozil

Advanced Life Sciences licenses ALS-499 from Argonne National Laboratory

Novartis Generics rebranded as Sandoz

Valentis licenses delivery technology to Juvaris

Patient enrollment begins in phase II trial of ThGRF in HIV-related lipodystrophy

Speedel acquires full rights to SPP-301 from Roche

EMEA hands down positive opinion on Humira

Ipsen acquires development rights to SJG-136 from Spirogen

Biovitrum and GSK to focus efforts on highly selective 5-HT2C receptor agonists

CeNeS divests three products, allocates profits

Wyeth and Takeda sign new partnership agreements

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...